Waters CorporationNYSE: WAT
Health Care · Life Sciences Tools & Services
$356.50
-0.14%
Vol: 616K
Research Digest
Friday, June 19, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Waters Q1 beats, raises 2026 guidance; FDA HPV clearance, stock +11.4%Positive▶
Q1 2026 revenue $1.27B (organic $747M, +13% reported), adj EPS $2.70 vs $2.31 consensus. Q2 guide $1.62B at midpoint, 3.7% above expectations. First quarter including BD Biosciences/Diagnostic Solutions ($17.5B spin-merge closed Feb 9). FDA cleared Onclarity HPV At-Home Self-Collection Kit. Evercore ISI upgraded to Outperform with $350 PT. Shares jumped 11.4% post-print.
May 20No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 19Waters Corp news flow highlights Fundsmith stake reveal on May 18, reinforcing institutional confidence post-BD spin-merge.Positive▶
On May 18, 2026, news flow focused on Waters Corp's Fundsmith stake disclosure and post-merger integration momentum following the $17.5B BD Biosciences spin-merge. Earlier in May, Waters delivered a strong Q1 2026 print (revenue $1.27B, organic growth +11%, EPS $2.70 +20%) that drove an 11.4% one-day stock pop and a guidance raise. The FDA's clearance of the Onclarity HPV At-Home Self-Collection Kit added a new reimbursed screening channel. This matters because Waters is rapidly diversifying beyond analytical chromatography into diagnostics. Bear case: integration risk and tariffs on instruments could weigh on margins.
May 18Waters Corp draws Fundsmith stake attention as BD spin-merge integration and FDA HPV clearances drive momentum.Positive▶
Waters Corporation's recent moves drew investor attention amid Fundsmith's stake disclosure and integration of Becton Dickinson's $17.5 billion Biosciences and Diagnostic Solutions spin-merge. Q1 2026 results released May 5 exceeded expectations with total revenue of $1.27 billion and adjusted EPS of $2.70 (17% above consensus), including $747 million of organic revenue and $520 million from the acquired BD businesses. The U.S. FDA cleared Waters' Onclarity HPV At-Home Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping, opening a reimbursed at-home screening channel. Q2 2026 revenue guidance of $1.62 billion at midpoint was 3.7% above expectations, with adjusted EPS guidance of $2.95-$3.05. Shares jumped 11.4% on earnings and Evercore ISI upgraded to Outperform with $350 target. The stock traded around $333 in mid-May.
May 15Waters Corp jumped 11.4% after Q1 2026 earnings beat (revenue $1.27B, adjusted EPS $2.70 up 20%) and raised FY guidance, with FDA clearance for Onclarity HPV self-collection kit and Evercore upgrade to Outperform reinforcing momentum.Positive▶
Waters reported Q1 2026 revenue of $1.27B (up 91.5% YoY reflecting completed BD Biosciences & Diagnostic Solutions combination) including $747M organic and $520M from BD transaction. Adjusted EPS grew 20% to $2.70. Management raised full-year 2026 revenue and EPS guidance. The FDA cleared Waters' Onclarity HPV At-Home Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping, opening a reimbursed at-home screening channel across major US payors; shares popped ~4.5% on the clearance. Evercore ISI upgraded to Outperform with $350 PT citing achievable Q1 numbers and stronger 2H, while Goldman reinstated Buy with $375 PT. Deutsche Bank trimmed PT to $330 (Hold). Risk: integration execution from BD merger and FX/instrument cycle in life-science tools.
May 14Waters jumps 11.4% on May 5 after Q1 EPS of $2.70 beats and FY26 guidance raised to $14.40–$14.60 EPS amid BD biosciences merger integration.Positive▶
Waters Corporation reported Q1 2026 revenue of $1.267B, beating the $1.21B estimate by 4.5%, including $747M organic revenue and $520M from the newly acquired BD Biosciences & Diagnostic Solutions businesses. Adjusted EPS came in at $2.70, a meaningful beat. The company raised full-year 2026 guidance to revenue of $6.405B–$6.455B and adjusted EPS of $14.40–$14.60. Shares jumped 11.4% on May 5. Separately, the FDA cleared Waters' Onclarity HPV At-Home Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping, opening a reimbursed at-home screening channel. The $17.5B BD Biosciences merger (Reverse Morris Trust) continues to drive transformation. Evercore ISI upgraded to Outperform with a $350 target. Stock closed $355.13 on May 8.
May 13Waters Corp jumps 11% on Q1 EPS beat, raised 2026 guidance, FDA Onclarity HPV clearance, and Evercore upgradePositive▶
Waters Corporation reported Q1 2026 on May 5 with adjusted EPS of $2.70 (beating consensus by 16.88%) and revenue of $1.267 billion (beating by 5.30%); the print included $747 million of organic revenue plus $520 million from the newly combined BD Biosciences & Diagnostic Solutions businesses acquired February 9, 2026. Organic revenue grew 13% as reported and 11% in constant currency. Shares rose roughly 11.4% on the beat plus raised full-year guidance, with Q2 adjusted EPS guided to $2.95-$3.05. The FDA cleared Waters' Onclarity HPV At-Home Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping, unlocking a reimbursed at-home screening channel across major U.S. payors. Evercore ISI upgraded WAT to Outperform with a $350 target, citing visibility into a stronger second half. Waters also launched the omniDAWN extended-range MALS detector targeting biologics, viral vectors, and lipid nanoparticles.
May 12Waters surges 11.4% after Q1 EPS of $2.70 beats by 17%, FDA clears HPV at-home test, and 2026 EPS guidance lifted to $14.40-14.60Positive▶
Waters Corporation jumped 11.4% after reporting Q1 2026 EPS of $2.70 (vs estimates by 17%) on revenue of $1.27B (5.3% above expectations) — the fourth consecutive earnings beat. Q1 included $747M organic plus $520M from the recently acquired BD Biosciences & Diagnostic Solutions businesses. The pharmaceutical segment grew 14% on broad-based demand from large drugmakers, CMOs, and Chinese biotech. The FDA cleared the Onclarity HPV At-Home Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping, opening a reimbursed at-home screening channel across major US payors. Waters raised 2026 guidance: revenue to $6.405-6.455B, adjusted EPS to $14.40-14.60; Q2 EPS guided to $2.95-3.05. The omniDAWN extended-range multi-angle light scattering detector launches into biologics/viral vector markets. Evercore ISI upgraded to Outperform with $350 target.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| TMOTHERMO | $466.53 | +1.05% | +2.8% | 17.1x | 0.87 | $172.7B |
| DHRDANAHER | $177.74 | -0.01% | +3.5% | 19.1x | 0.83 | $125.4B |
| AAGILENT | $127.36 | +2.44% | +11.7% | 19.2x | 1.26 | $35.9B |
| WATWATERS | $356.50 | -0.14% | +4.1% | 21.6x | 1.20 | $34.9B |
| IQVIQVIA | $168.20 | -1.45% | -2.2% | 11.8x | 1.22 | $28.0B |
| MTDMETTLER | $1,150.03 | +1.81% | +5.7% | 22.3x | 1.26 | $23.1B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.